STANDARD BIOTOOLS INC.
No SEC Form 4 filings for $LAB in the last 30 days.
See all $LAB insider activity →STANDARD BIOTOOLS INC. (LAB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Standard BioTools Provides Update on Sale of Mass Cytometry Business Standard BioTools Enters into New Purchase Agreement with Element Biosystems, a subsidiary of GMT Venture, After Determining GMT Venture’s Unsolicited Acquisition Proposal as Superior BOSTON, Mass.,
Lab (LAB) fell more than 13% in 24 hours, extending a downtrend, with daily volume up 335% to about $50M and a volume-to-market-cap ratio near 81%, according to the article. It cites technical rejection around $0.15, rising open interest above $124M, exchange hot-wallet selling (KuCoin), and protocol daily revenue dropping from about $191K to about $6.2K.
STANDARD BIOTOOLS INC. (LAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Standard BioTools Reports Second Quarter 2026 Financial Results BOSTON, Mass., August 5, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended June 30, 2026. Recent
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning LAB (STANDARD BIOTOOLS INC.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent LAB coverage spans corporate actions, crypto and earnings.
The cash proceeds improve Standard BioTools' balance sheet and increase the net cash component used in the Treeline merger calculation.
Momentum is bearish with evidence of short positioning and exchange-driven selling, but dip-buying signals could enable a relief rally if support holds.
Near-term trading focus is on merger-close probability and the implications of withdrawing full-year revenue guidance.
Cash inflow and removal of future earnout/royalty obligations, plus a separate plan to sell its mass cytometry business for $5M with potential $5M contingent consideration.
Margin expansion and Latin America growth partially offset currency headwinds and weaker Mexico and U.S. demand, with management expecting gradual H2 2026 recovery.
AlphAI scores every news story that mentions LAB with an AI model for sentiment and relevance, and aggregates insider trades from STANDARD BIOTOOLS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
STANDARD BIOTOOLS INC. (LAB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Standard BioTools Provides Update on Sale of Mass Cytometry Business Standard BioTools Enters into New Purchase Agreement with Element Biosystems, a subsidiary of GMT Venture, After Determining GMT Venture’s Unsolicited Acquisition Proposal as Superior BOSTON, Mass.,
2 min readLab (LAB) fell more than 13% in 24 hours, extending a downtrend, with daily volume up 335% to about $50M and a volume-to-market-cap ratio near 81%, according to the article. It cites technical rejection around $0.15, rising open interest above $124M, exchange hot-wallet selling (KuCoin), and protocol daily revenue dropping from about $191K to about $6.2K.
5 min readSTANDARD BIOTOOLS INC. (LAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Standard BioTools Reports Second Quarter 2026 Financial Results BOSTON, Mass., August 5, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended June 30, 2026. Recent
6 min readSTANDARD BIOTOOLS INC. (LAB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001162194 0001162194 2026-07-24 2026-07-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 24, 2026
4 min readGenomma Lab Internacional SAB de CV Class B (LAB/B) reported consolidated sales down 6% year over year, citing currency headwinds and softer demand in Mexico and the U.S. Gross margin expanded, lifting net income 5.5%. Latin America grew, and management expects gradual recovery in H2 2026.
1 min readThe article says LAB token ($LAB) rose about 47% in 24 hours on higher volume and liquidity. It cites a breakout from a descending triangle, with a key resistance range of $0.33 to $0.36, and notes open interest around $129M. It also highlights daily token unlocks of 1.87M LAB (about $355K) and selling pressure from derivatives and CVD.
4 min readLabrador Gold Corp. (TSX.V: LAB) says exploration at its Mariposa and Eureka Dome projects in Yukon is underway. It closed the first tranche of a May 8, 2026 option deal with Pacific Ridge Exploration Limited, paying $100,000 and issuing 800,000 shares. Soil sampling is ongoing; an airborne survey was delayed by weather.
5 min readSTANDARD BIOTOOLS INC. (LAB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 lab-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 STANDARD BIOTOOLS INC. EQUITY INCENTIVE PLAN 1. Purposes of the Plan . The purposes of this Plan are (a) to attract and retain the best available personnel for positions of substantial responsibility, (b) to provide additional
3 min readSTANDARD BIOTOOLS INC. (LAB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 tm2617100d1_ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among TREELINE BIOSCIENCES, INC., STANDARD BIOTOOLS INC., and SIRI MERGER SUB, INC. Dated as of June 6, 2026 TABLE OF CONTENTS Page Article I THE MERGER; CLOSI
6 min readShort interest in Standard BioTools Inc. (NASDAQ:LAB) decreased by 18.5% in March, totaling 8,281,198 shares as of March 13th. Institutional investors now own about 53.74% of the stock, with several large investors increasing their stakes. The company recently beat revenue and EPS estimates but remains unprofitable, with analysts holding a consensus "Reduce" rating and a target price of $1.35.
2 min read
